<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550106</url>
  </required_header>
  <id_info>
    <org_study_id>CIGE025EFR02</org_study_id>
    <nct_id>NCT02550106</nct_id>
  </id_info>
  <brief_title>Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment</brief_title>
  <acronym>SUNRISE</acronym>
  <official_title>A Phase IV, Multicenter, Single-arm and Open-label Study With Omalizumab (Xolair®) in Chronic Spontaneous Urticaria (CSU) Patients Who Remain Symptomatic Despite Antihistamine (H1) Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the proportion of patients with an urticaria control test [UCT] score of greater
      than or equal to 12 at Week 12.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 22, 2015</start_date>
  <completion_date type="Actual">January 11, 2016</completion_date>
  <primary_completion_date type="Actual">January 11, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants With an Urticaria Control Test [UCT] Score of Greater Than or Equal to 12</measure>
    <time_frame>WEEK 12</time_frame>
    <description>Number of participants with an Urticaria Control Test score of greater than or equal to 12 at Week 12
The UCT is a simple 4-item tool. A score between 0 and 4 is assigned to every answer option. Subsequently, the scores for all 4 questions are summed up. Accordingly, the minimum and maximum UCT scores are 0 and 16, with 16 points indicating complete disease control.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With UAS7≤6 (Patients Achieving Disease Control), in Adult Patients With CSU, With or Without the Presence of Angioedema</measure>
    <time_frame>WEEK 12</time_frame>
    <description>2 patients with angioedema status were missing at baseline and not included</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSU Disease Activity Using the Urticaria Activity Score (UAS7), With or Without the Presence of Angioedema</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>A total score of UAS7 is calculated by adding for 7 days the daily UAS. The UAS7 is the sum of the daily UAS over 7 days before baseline and W12. The UAS7 score ranges from 0 to 42 with higher scores reflecting higher activity of the disease.
Scores were categorized into five diseases states : urticaria‐free (score =0), well‐controlled (scores 1-6), mild (scores 7-15), moderate (scores 16-27) and severe urticaria (scores 28-42).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urticaria Control Test (UCT) Score According to the Presence of Angioedema at Baseline and Week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>The UCT is a questionnaire collecting retrospective information over the last 4 weeks before baseline and W12.
The UCT score ranges from 0 to 16 with higher scores reflecting lower control of the disease.
A score of ≥12 indicates well-controlled urticaria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control of the CSU Using the UCT Score for Patients in Extension Treatment Period Phase at Week 16, With or Without the Presence of Angioedema</measure>
    <time_frame>week 16</time_frame>
    <description>The UCT is a simple 4-item tool. A score between 0 and 4 is assigned to every answer option. Subsequently, the scores for all 4 questions are summed up. Accordingly, the minimum and maximum UCT scores are 0 and 16, with 16 points indicating complete disease control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control of the CSU Using the UCT Score for Patients in Extension Treatment Period Phase at Week 20, With or Without the Presence of Angioedema</measure>
    <time_frame>week 20</time_frame>
    <description>The UCT is a simple 4-item tool. A score between 0 and 4 is assigned to every answer option. Subsequently, the scores for all 4 questions are summed up. Accordingly, the minimum and maximum UCT scores are 0 and 16, with 16 points indicating complete disease control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control of the CSU Using the UCT Score for Patients in Extension Treatment Period Phase at Week 24, With or Without the Presence of Angioedema</measure>
    <time_frame>week 24</time_frame>
    <description>The UCT is a simple 4-item tool. A score between 0 and 4 is assigned to every answer option. Subsequently, the scores for all 4 questions are summed up. Accordingly, the minimum and maximum UCT scores are 0 and 16, with 16 points indicating complete disease control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control of the CSU Using the UCT Score for Patients in Extension Treatment Period Phase at Week 28, With or Without the Presence of Angioedema</measure>
    <time_frame>week 28</time_frame>
    <description>The UCT is a simple 4-item tool. A score between 0 and 4 is assigned to every answer option. Subsequently, the scores for all 4 questions are summed up. Accordingly, the minimum and maximum UCT scores are 0 and 16, with 16 points indicating complete disease control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Quality of Life Using the Chronic Urticaria Quality of Life (CU-QoL) Questionnaire</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>The Cu-QoL is a questionnaire collecting retrospective information over the last 2 weeks before baseline and W12.
The CU-QoL total score is transformed to range from 0 to 100, with higher scores indicating worse Health Related Quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Angioedema Quality of Life (AE-QoL)</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>The angioedema Quality of Life Questionnaire is a valuable tool to assess changes of QoL impairment in angioedema patients.
The results of all the answered questions are summed up and transferred to a scale ranging from 0 to 100, with higher scores indicative of a higher QoL impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>The Dermatology life Quality Index (DLQI) is a ten-question questionnaire used to measure the impact of skin disease on the quality of life of an affected person. It is designed for people aged 16 years and above. Each question is scored from 0 to 3, giving a possible score range form 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angioedema Activity Using the Angioedema Activity Score (AAS)</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>The Angioedema Activity Score (AAS) was completed by patients on a daily basis. The AAS is a validated questionnaire to determine the severity and impact of the angioedema episode. Te daily AAS values are added over 7 days before baseline and W12. Weekly AAS (AAS7) scores range from 0 to 105, with higher scores indicative of a higher disease activity.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>CHRONIC SPONTANEOUS URTICARIA</condition>
  <arm_group>
    <arm_group_label>OMALIZUMAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sub cutaneous injections of 300 mg every 4 weeks until Week 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OMALIZUMAB</intervention_name>
    <description>sub cutaneous injections of 300 mg every 4 weeks until Week 8.</description>
    <arm_group_label>OMALIZUMAB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged between 18 and 75 years.

          -  Diagnosis of CSU for ≥ 6 months and an inadequate response to nsH1 antihistamines at
             the time of the request, as defined by the following:

          -  The presence of itch and hives for &gt; 6 consecutive weeks at any time prior to
             enrollment, despite current use of H1 antihistamine therapy during this time period.

          -  Weekly UAS7 score (range 0 to 42) 16 and UCT score (range 0 to 16) &lt; 8 prior to
             enrollment (Day 1)

          -  Current use of an H1 antihistamine for CSU on the day of the initial visit and Day

          -  Informed consent

        Exclusion Criteria:

          -  Treatment with an investigational agent within 30 days before enrollment.

          -  Routine (daily or every other day during 5 or more consecutive days) doses of the
             following medications within 30 days prior to Day -7: systemic or cutaneous (topical)
             corticosteroids (prescription or over the counter), hydroxychloroquine, methotrexate,
             cyclosporine, or cyclophosphamide.

          -  Intravenous (i.v.) immunoglobulin G or plasmapheresis within 30 days prior to Day -7

          -  Regular (daily/every other day) doxepin (oral) use within 14 days prior to Day -7.

          -  Any H2 antihistamine use within 7 days prior to Day -7.

          -  Any leukotriene receptor antagonist (LTRA) (montelukast or zafirlukast) within 7 days
             prior to Day 7.

          -  Concomitant use of cyclosporine or any other immunosuppressive agent.

          -  Hypersensitivity to omalizumab or any component of the formulation.

          -  History of anaphylactic shock.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CLAIRE BERNIER TAUGOURDEAU</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL HOTEL DIEU - NANTES CEDEX 1</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PASCAL JOLY</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL CHARLES NICOLLE - ROUEN CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>LUDOVIC MARTIN</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOTEL DIEU - ANGERS CEDEX 9</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GERARD GUILLET</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR LA MILETRIE - POITIERS CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PATRICE PLANTIN</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHI DE CORNOUAILLE - QUIMPER CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ALAIN DUPUY</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL PONTCHAILLOU - RENNES CEDEX 9</affiliation>
  </overall_official>
  <overall_official>
    <last_name>EVELYNE COLLET</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SITE DU BOCAGE - DIJON CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ANNICK BARBAUD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAUX DE BRABOIS - VANDOEUVRE LES NANCY CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ZIAD REGUIAI</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL ROBERT DEBRE - REIMS CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>FABIEN PELLETIER</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL JEAN MINJOZ - BESANCON CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>DELPHINE STAUMONT SALLE</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL CLAUDE HURIEZ- LILLE CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JULIETTE JEGOU</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH DE CHALONS EN CHAMPAGNE - CHALONS EN CHAMPAGNE CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>EMMANUELLE AMSLER</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL TENON - PARIS CEDEX 20</affiliation>
  </overall_official>
  <overall_official>
    <last_name>OLIVIER CHOSIDOW</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL HENRI MONDOR - CRETEIL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>VINCENT DESCAMPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL BICHAT CLAUDE BERNARD - PARIS CEDEX 18</affiliation>
  </overall_official>
  <overall_official>
    <last_name>EMMANUEL MAHE</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH VICTOR DUPOUY - ARGENTEUIL CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>LILIANE LAROCHE</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL AVICENNE - BOBIGNY CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GERMAINE GABISON</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL SAINT LOUIS - PARIS CEDEX 10</affiliation>
  </overall_official>
  <overall_official>
    <last_name>SELIM ARACTINGI</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL COCHIN - PARIS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>LAURENCE BOUILLET</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU DE GRENOBLE - LA TRONCHE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JEAN-JACQUES GROB</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL TIMONE - MARSEILLE CEDEX 05</affiliation>
  </overall_official>
  <overall_official>
    <last_name>FREDERIC CAMBAZARD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT ETIENNE - ST PRIEST EN JAREZ CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>THIERRY BOYE</last_name>
    <role>Principal Investigator</role>
    <affiliation>HIA SAINTE ANNE - TOULON CEDEX 9</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JEAN-PHILIPPE LACOUR</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL DE L'ARCHET - NICE CEDEX 3</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PHILIPPE BERBIS</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL NORD- MARSEILLE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>LAURENT MEUNIER</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL CAREMEAU - NIMES CEDEX 9</affiliation>
  </overall_official>
  <overall_official>
    <last_name>FRANCOISE GIORDANO LABADIE</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL LARREY - TOULOUSE CEDEX 9</affiliation>
  </overall_official>
  <overall_official>
    <last_name>NADIA RAISON PEYRON</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL ST ELOI - MONTPELLIER CEDEX 5</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MARIE CHRISTINE FERRIER LE BOUEDEC</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU ESTAING - CLERMONT FERRAND</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MARIE SYLVIE DOUTRE</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL DE HAUT LEVEQUE - PESSAC CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BRIGITTE MILPIED</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL ST ANDRE - BORDEAUX CEDEX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>CHRISTOPHE BEDANE</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL DUPUYTREN - LIMOGES CEDEX 1</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PHILIPPE MODIANO</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL ST VINCENT DE PAUL - LILLE CEDEX</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <state>Cedex 10</state>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Limoges cedex</city>
        <state>Haute Vienne</state>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulon Cedex 9</city>
        <state>Val De Marne</state>
        <zip>83800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Angers cedex 09</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Argenteuil</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Besancon Cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bobigny Cedex</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chalons-en-Champagne</city>
        <zip>51005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clermont Ferrand cedex 1</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon cedex 04</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille Cedex 05</city>
        <zip>13885</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nantes</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nimes Cedex</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quimper</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reims</city>
        <zip>51090</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rennes Cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 9, 2015</study_first_submitted>
  <study_first_submitted_qc>September 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <results_first_submitted>January 10, 2017</results_first_submitted>
  <results_first_submitted_qc>February 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 25, 2020</results_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CHRONIC SPONTANEOUS URTICARIA</keyword>
  <keyword>OMALIZUMAB</keyword>
  <keyword>URTICARIA CONTROL TEST</keyword>
  <keyword>IGE025</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Full Analysis Set</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>OMALIZUMAB</title>
          <description>sub cutaneous injections of 300 mg every 4 weeks until Week 8</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OMALIZUMAB</title>
          <description>sub cutaneous injections of 300 mg every 4 weeks until Week 8</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="136"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.4" spread="12.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With an Urticaria Control Test [UCT] Score of Greater Than or Equal to 12</title>
        <description>Number of participants with an Urticaria Control Test score of greater than or equal to 12 at Week 12
The UCT is a simple 4-item tool. A score between 0 and 4 is assigned to every answer option. Subsequently, the scores for all 4 questions are summed up. Accordingly, the minimum and maximum UCT scores are 0 and 16, with 16 points indicating complete disease control.</description>
        <time_frame>WEEK 12</time_frame>
        <population>(Full analysis set, LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>OMALIZUMAB With ANGIOEDEMA</title>
            <description>sub cutaneous injections of 300 mg every 4 weeks until W8</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With an Urticaria Control Test [UCT] Score of Greater Than or Equal to 12</title>
          <description>Number of participants with an Urticaria Control Test score of greater than or equal to 12 at Week 12
The UCT is a simple 4-item tool. A score between 0 and 4 is assigned to every answer option. Subsequently, the scores for all 4 questions are summed up. Accordingly, the minimum and maximum UCT scores are 0 and 16, with 16 points indicating complete disease control.</description>
          <population>(Full analysis set, LOCF)</population>
          <units>percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="66.9" upper_limit="82.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With UAS7≤6 (Patients Achieving Disease Control), in Adult Patients With CSU, With or Without the Presence of Angioedema</title>
        <description>2 patients with angioedema status were missing at baseline and not included</description>
        <time_frame>WEEK 12</time_frame>
        <population>Full Analysis Set
2 patients with angioedema status missing at baseline were not included so that FAS = 83 + 51 + 2= 136</population>
        <group_list>
          <group group_id="O1">
            <title>OMALIZUMAB With ANGIOEDEMA</title>
            <description>sub cutaneous injections of 300 mg every 4 weeks until W8</description>
          </group>
          <group group_id="O2">
            <title>OMALIZUMAB Without Angioedema</title>
            <description>sub cutaneaous injections of 300 mg every 4 weeks until Week 8</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With UAS7≤6 (Patients Achieving Disease Control), in Adult Patients With CSU, With or Without the Presence of Angioedema</title>
          <description>2 patients with angioedema status were missing at baseline and not included</description>
          <population>Full Analysis Set
2 patients with angioedema status missing at baseline were not included so that FAS = 83 + 51 + 2= 136</population>
          <units>percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" lower_limit="58.2" upper_limit="79.5"/>
                    <measurement group_id="O2" value="63.8" lower_limit="48.5" upper_limit="77.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSU Disease Activity Using the Urticaria Activity Score (UAS7), With or Without the Presence of Angioedema</title>
        <description>A total score of UAS7 is calculated by adding for 7 days the daily UAS. The UAS7 is the sum of the daily UAS over 7 days before baseline and W12. The UAS7 score ranges from 0 to 42 with higher scores reflecting higher activity of the disease.
Scores were categorized into five diseases states : urticaria‐free (score =0), well‐controlled (scores 1-6), mild (scores 7-15), moderate (scores 16-27) and severe urticaria (scores 28-42).</description>
        <time_frame>baseline and week 12</time_frame>
        <population>Full Analysis Set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>OMALIZUMAB With ANGIOEDEMA</title>
            <description>sub cutaneous injections of 300 mg every 4 weeks until W8</description>
          </group>
          <group group_id="O2">
            <title>OMALIZUMAB Without ANGIOEDEMA</title>
            <description>sub cutaneous injections of 300 mg every 4 weeks until W8</description>
          </group>
        </group_list>
        <measure>
          <title>CSU Disease Activity Using the Urticaria Activity Score (UAS7), With or Without the Presence of Angioedema</title>
          <description>A total score of UAS7 is calculated by adding for 7 days the daily UAS. The UAS7 is the sum of the daily UAS over 7 days before baseline and W12. The UAS7 score ranges from 0 to 42 with higher scores reflecting higher activity of the disease.
Scores were categorized into five diseases states : urticaria‐free (score =0), well‐controlled (scores 1-6), mild (scores 7-15), moderate (scores 16-27) and severe urticaria (scores 28-42).</description>
          <population>Full Analysis Set (FAS)</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7" spread="7.32"/>
                    <measurement group_id="O2" value="29.2" spread="6.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="10.08"/>
                    <measurement group_id="O2" value="6.5" spread="9.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urticaria Control Test (UCT) Score According to the Presence of Angioedema at Baseline and Week 12</title>
        <description>The UCT is a questionnaire collecting retrospective information over the last 4 weeks before baseline and W12.
The UCT score ranges from 0 to 16 with higher scores reflecting lower control of the disease.
A score of ≥12 indicates well-controlled urticaria.</description>
        <time_frame>baseline and week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>OMALIZUMAB With ANGIOEDEMA</title>
            <description>sub cutaneous injections of 300 mg every 4 weeks until W8</description>
          </group>
          <group group_id="O2">
            <title>OMALIZUMAB Without ANGIOEDEMA</title>
            <description>sub cutaneous injections of 300 mg every 4 weeks until W8</description>
          </group>
        </group_list>
        <measure>
          <title>Urticaria Control Test (UCT) Score According to the Presence of Angioedema at Baseline and Week 12</title>
          <description>The UCT is a questionnaire collecting retrospective information over the last 4 weeks before baseline and W12.
The UCT score ranges from 0 to 16 with higher scores reflecting lower control of the disease.
A score of ≥12 indicates well-controlled urticaria.</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="2.06"/>
                    <measurement group_id="O2" value="3.6" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="3.95"/>
                    <measurement group_id="O2" value="12.9" spread="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Control of the CSU Using the UCT Score for Patients in Extension Treatment Period Phase at Week 16, With or Without the Presence of Angioedema</title>
        <description>The UCT is a simple 4-item tool. A score between 0 and 4 is assigned to every answer option. Subsequently, the scores for all 4 questions are summed up. Accordingly, the minimum and maximum UCT scores are 0 and 16, with 16 points indicating complete disease control.</description>
        <time_frame>week 16</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>OMALIZUMAB With ANGIOEDEMA</title>
            <description>sub cutaneous injections of 300 mg every 4 weeks until W8</description>
          </group>
          <group group_id="O2">
            <title>OMALIZUMAB Without ANGIOEDEMA</title>
            <description>sub cutaneous injections of 300 mg every 4 weeks until W8</description>
          </group>
        </group_list>
        <measure>
          <title>Control of the CSU Using the UCT Score for Patients in Extension Treatment Period Phase at Week 16, With or Without the Presence of Angioedema</title>
          <description>The UCT is a simple 4-item tool. A score between 0 and 4 is assigned to every answer option. Subsequently, the scores for all 4 questions are summed up. Accordingly, the minimum and maximum UCT scores are 0 and 16, with 16 points indicating complete disease control.</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="2.96"/>
                    <measurement group_id="O2" value="13.4" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Control of the CSU Using the UCT Score for Patients in Extension Treatment Period Phase at Week 20, With or Without the Presence of Angioedema</title>
        <description>The UCT is a simple 4-item tool. A score between 0 and 4 is assigned to every answer option. Subsequently, the scores for all 4 questions are summed up. Accordingly, the minimum and maximum UCT scores are 0 and 16, with 16 points indicating complete disease control.</description>
        <time_frame>week 20</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>OMALIZUMAB With ANGIOEDEMA</title>
            <description>sub cutaneous injections of 300 mg every 4 weeks until W8</description>
          </group>
          <group group_id="O2">
            <title>OMALIZUMAB Without ANGIOEDEMA</title>
            <description>sub cutaneous injections of 300 mg every 4 weeks until W8</description>
          </group>
        </group_list>
        <measure>
          <title>Control of the CSU Using the UCT Score for Patients in Extension Treatment Period Phase at Week 20, With or Without the Presence of Angioedema</title>
          <description>The UCT is a simple 4-item tool. A score between 0 and 4 is assigned to every answer option. Subsequently, the scores for all 4 questions are summed up. Accordingly, the minimum and maximum UCT scores are 0 and 16, with 16 points indicating complete disease control.</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="2.40"/>
                    <measurement group_id="O2" value="13.3" spread="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Control of the CSU Using the UCT Score for Patients in Extension Treatment Period Phase at Week 24, With or Without the Presence of Angioedema</title>
        <description>The UCT is a simple 4-item tool. A score between 0 and 4 is assigned to every answer option. Subsequently, the scores for all 4 questions are summed up. Accordingly, the minimum and maximum UCT scores are 0 and 16, with 16 points indicating complete disease control</description>
        <time_frame>week 24</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>OMALIZUMAB With ANGIOEDEMA</title>
            <description>sub cutaneous injections of 300 mg every 4 weeks until W8</description>
          </group>
          <group group_id="O2">
            <title>OMALIZUMAB Without ANGIOEDEMA</title>
            <description>sub cutaneous injections of 300 mg every 4 weeks until W8</description>
          </group>
        </group_list>
        <measure>
          <title>Control of the CSU Using the UCT Score for Patients in Extension Treatment Period Phase at Week 24, With or Without the Presence of Angioedema</title>
          <description>The UCT is a simple 4-item tool. A score between 0 and 4 is assigned to every answer option. Subsequently, the scores for all 4 questions are summed up. Accordingly, the minimum and maximum UCT scores are 0 and 16, with 16 points indicating complete disease control</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="2.14"/>
                    <measurement group_id="O2" value="13.4" spread="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Control of the CSU Using the UCT Score for Patients in Extension Treatment Period Phase at Week 28, With or Without the Presence of Angioedema</title>
        <description>The UCT is a simple 4-item tool. A score between 0 and 4 is assigned to every answer option. Subsequently, the scores for all 4 questions are summed up. Accordingly, the minimum and maximum UCT scores are 0 and 16, with 16 points indicating complete disease control.</description>
        <time_frame>week 28</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>OMALIZUMAB With ANGIOEDEMA</title>
            <description>sub cutaneous injections of 300 mg every 4 weeks until W8</description>
          </group>
          <group group_id="O2">
            <title>OMALIZUMAB Without ANGIOEDEMA</title>
            <description>sub cutaneous injections of 300 mg every 4 weeks until W8</description>
          </group>
        </group_list>
        <measure>
          <title>Control of the CSU Using the UCT Score for Patients in Extension Treatment Period Phase at Week 28, With or Without the Presence of Angioedema</title>
          <description>The UCT is a simple 4-item tool. A score between 0 and 4 is assigned to every answer option. Subsequently, the scores for all 4 questions are summed up. Accordingly, the minimum and maximum UCT scores are 0 and 16, with 16 points indicating complete disease control.</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="3.54"/>
                    <measurement group_id="O2" value="12.0" spread="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Quality of Life Using the Chronic Urticaria Quality of Life (CU-QoL) Questionnaire</title>
        <description>The Cu-QoL is a questionnaire collecting retrospective information over the last 2 weeks before baseline and W12.
The CU-QoL total score is transformed to range from 0 to 100, with higher scores indicating worse Health Related Quality of life.</description>
        <time_frame>baseline and week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>OMALIZUMAB With ANGIOEDEMA</title>
            <description>sub cutaneous injections of 300 mg every 4 weeks until W8</description>
          </group>
          <group group_id="O2">
            <title>OMALIZUMAB Without ANGIOEDEMA</title>
            <description>sub cutaneous injections of 300 mg every 4 weeks until W8</description>
          </group>
        </group_list>
        <measure>
          <title>The Quality of Life Using the Chronic Urticaria Quality of Life (CU-QoL) Questionnaire</title>
          <description>The Cu-QoL is a questionnaire collecting retrospective information over the last 2 weeks before baseline and W12.
The CU-QoL total score is transformed to range from 0 to 100, with higher scores indicating worse Health Related Quality of life.</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9" spread="15.64"/>
                    <measurement group_id="O2" value="62.4" spread="17.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5" spread="13.33"/>
                    <measurement group_id="O2" value="33.3" spread="13.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Angioedema Quality of Life (AE-QoL)</title>
        <description>The angioedema Quality of Life Questionnaire is a valuable tool to assess changes of QoL impairment in angioedema patients.
The results of all the answered questions are summed up and transferred to a scale ranging from 0 to 100, with higher scores indicative of a higher QoL impairment</description>
        <time_frame>baseline and week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>OMALIZUMAB With ANGIOEDEMA</title>
            <description>sub cutaneous injections of 300 mg every 4 weeks until W8</description>
          </group>
        </group_list>
        <measure>
          <title>The Angioedema Quality of Life (AE-QoL)</title>
          <description>The angioedema Quality of Life Questionnaire is a valuable tool to assess changes of QoL impairment in angioedema patients.
The results of all the answered questions are summed up and transferred to a scale ranging from 0 to 100, with higher scores indicative of a higher QoL impairment</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.88" spread="22.474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.40" spread="20.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Dermatology Life Quality Index (DLQI)</title>
        <description>The Dermatology life Quality Index (DLQI) is a ten-question questionnaire used to measure the impact of skin disease on the quality of life of an affected person. It is designed for people aged 16 years and above. Each question is scored from 0 to 3, giving a possible score range form 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).</description>
        <time_frame>baseline and week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>OMALIZUMAB With ANGIOEDEMA</title>
            <description>sub cutaneous injections of 300 mg every 4 weeks until W8</description>
          </group>
          <group group_id="O2">
            <title>OMALIZUMAB Without Angioedema</title>
            <description>sub cutaneaous injections of 300 mg every 4 weeks until Week 8</description>
          </group>
        </group_list>
        <measure>
          <title>The Dermatology Life Quality Index (DLQI)</title>
          <description>The Dermatology life Quality Index (DLQI) is a ten-question questionnaire used to measure the impact of skin disease on the quality of life of an affected person. It is designed for people aged 16 years and above. Each question is scored from 0 to 3, giving a possible score range form 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="5.39"/>
                    <measurement group_id="O2" value="13.2" spread="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="3.95"/>
                    <measurement group_id="O2" value="2.7" spread="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angioedema Activity Using the Angioedema Activity Score (AAS)</title>
        <description>The Angioedema Activity Score (AAS) was completed by patients on a daily basis. The AAS is a validated questionnaire to determine the severity and impact of the angioedema episode. Te daily AAS values are added over 7 days before baseline and W12. Weekly AAS (AAS7) scores range from 0 to 105, with higher scores indicative of a higher disease activity.</description>
        <time_frame>baseline and week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>OMALIZUMAB With ANGIOEDEMA</title>
            <description>sub cutaneous injections of 300 mg every 4 weeks until W8</description>
          </group>
        </group_list>
        <measure>
          <title>Angioedema Activity Using the Angioedema Activity Score (AAS)</title>
          <description>The Angioedema Activity Score (AAS) was completed by patients on a daily basis. The AAS is a validated questionnaire to determine the severity and impact of the angioedema episode. Te daily AAS values are added over 7 days before baseline and W12. Weekly AAS (AAS7) scores range from 0 to 105, with higher scores indicative of a higher disease activity.</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7" spread="27.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="10.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from first dose of study treatment until end of study treatment at week 12</time_frame>
      <desc>An adverse event (AE) is any sign or symptom that occurs during the study treatment plus the # days post treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>Omalizumab 300 mg</title>
          <description>Omalizumab 300 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CERVICAL VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>FRACTURED SACRUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>LIGAMENT SPRAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>OBESITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>FOOT DEFORMITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>SACROILIITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>BLADDER DILATATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PHARYNGEAL OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No placebo arm and limited duration of the study (3 months for the main period)</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>(862) 778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

